QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Results from Human Oral Nicotine Study Evaluating DehydraTECH(TM)-Nicotine
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting results from its 2023 human oral nicotine study NIC-H22-1. The study compared Lexaria’s DehydraTECH(TM)-Nicotine tobacco-free pouch to two world-leading brands: ZYN(R) and on!(R) ZYN(R) is from Swedish Match and on! comes from Altria Group Inc. subsidiary Helix Innovations LLC. According to the report, DehydraTECH-Nicotine reached maximum blood saturation levels faster than either of the two other brands. In addition, superior subjective performance characteristics were observed in the study. Specifically, Lexaria’s oral nicotine pouch was significantly faster in the median time required to reach comparable maximum nicotine concentrations…